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Abstract
Chikungunya virus (CHIKV) is a reemerging mosquito-borne pathogen that has recently caused devastating urban
epidemics of severe and sometimes chronic arthralgia. As with most other mosquito-borne viral diseases, control relies on
reducing mosquito populations and their contact with people, which has been ineffective in most locations. Therefore,
vaccines remain the best strategy to prevent most vector-borne diseases. Ideally, vaccines for diseases of resource-limited
countries should combine low cost and single dose efficacy, yet induce rapid and long-lived immunity with negligible risk of
serious adverse reactions. To develop such a vaccine to protect against chikungunya fever, we employed a rational
attenuation mechanism that also prevents the infection of mosquito vectors. The internal ribosome entry site (IRES) from
encephalomyocarditis virus replaced the subgenomic promoter in a cDNA CHIKV clone, thus altering the levels and host-
specific mechanism of structural protein gene expression. Testing in both normal outbred and interferon response-defective
mice indicated that the new vaccine candidate is highly attenuated, immunogenic and efficacious after a single dose.
Furthermore, it is incapable of replicating in mosquito cells or infecting mosquitoes in vivo. This IRES-based attenuation
platform technology may be useful for the predictable attenuation of any alphavirus.
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Introduction
Chikungunya (CHIK) virus (CHIKV) is a reemerging arboviral
pathogen that has recently caused explosive urban outbreaks
involving millions of persons in Africa and Asia. The virus was first
isolated from a human in Tanzania in 1953 during a major
epidemic [1], and derives its name from a Makonde word meaning
‘‘that which bends up,’’ which describes the posture observed in
afflicted persons. CHIKV typically causes a febrile illness and
severe joint pain, which is clinically similar to dengue fever. These
2 viruses also share similar endemic distributions in the Eastern
Hemisphere, resulting in many CHIKV cases being misdiagnosed
when laboratory testing is not available [2]. Large CHIK
outbreaks were described during the 1950’s and 60’s in India
and Southeast Asia [3,4]. However, it was not until 2005 that
CHIKV gained widespread public attention due to massive
outbreaks on islands of the Indian Ocean [5] and later in India [6]
and Southeast Asia [7]. In total, several million persons have been
affected [8,9]. On the Island of Reunion alone, ca. 300,000
persons or one-third of the population was affected [10]. Another
factor driving the resurgence of interest in CHIK is the detection
of occasional fatal cases, which were not documented before.
Previously, individuals who became severely ill typically presented
with hemorrhagic manifestations and occasionally shock
[11,12,13]. However, the recent outbreaks have been linked to
thousands of deaths in Reunion and India due to neurologic
disease [14,15,16].
CHIKV exists in two transmission cycles: an enzootic or sylvatic
cycle and an endemic/epidemic urban cycle. The African sylvatic
cycle likely involves several arboreal Aedes mosquitoes as vectors
and nonhuman primates as reservoir/amplifying hosts [17].
African outbreaks occur from direct enzootic spillover or when
CHIKV is introduced into an urban areas inhabited by the
anthropophilic mosquito vector, Aedes aegypti. [17,18]. More
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lished when the virus was introduced into Asia ca. 1950, and into
the Indian Ocean region, India and then Southeast Asia since
2005 [19]. A mutation in the E1 envelope glycoprotein gene that
results in an A226V amino acid substitution dramatically
increased the infectivity of some epidemic strains for an alternative
urban vector, Ae. albopictus [8,20]. The nearly ubiquitous
distribution of Ae. aegypti, and the expanding distribution of Ae.
albopictus into tropical and temperate regions of both hemispheres
has raised concern that CHIKV may spread outside of its previous
endemic region into the Western Hemisphere and Europe. The
latter scenario was realized in 2007 during a small epidemic in
Italy [21] and during autochthonous transmission in southern
France during 2010 (ProMED archive 20100926.3495).
CHIKV belongs to the family Togaviridae, genus Alphavirus,
whose members are enveloped virions that contain a positive
sense, single stranded, RNA genome of ,12 kb. The genome
encodes 4 non-structural proteins (nsP1-4) and 3 major structural
proteins (Capsid, E1, and E2 envelope glycoproteins)(Fig. 1A).
During replication, two distinct RNA’s are produced: the genomic
and subgenomic RNAs. A negative sense template RNA is also
produced. The nonstructural polyprotein open reading frame
(ORF) is translated via a cap-dependant mechanism from the
genomic RNA, whereas the structural protein gene ORF is
translated from the subgenomic RNA, also in a cap-dependent
manner. The subgenomic RNA is transcribed late during infection
from its promoter, which is found in the 39 end of the nsP4 gene
[22].
There is no licensed vaccine or therapeutic CHIK, so outbreaks
can only be controlled by preventing the exposure of people to
infected mosquito vectors. Scientists at the Walter Reed Army
Institute of Research produced an investigational vaccine called
181/clone 25 (hereafter called 181/25) during the 1980s. This
live-attenuated strain was generated via serial plaque-to-plaque
passages of a wild-type Thai CHIKV strain using MRC-5 cells
[23]. The virus is attenuated in both rodents and non-human
primates and is highly immunogenic in humans. However, during
phase II trials, strain 181/25 caused mild, transient arthralgia in 5
of 59 vaccinees [24]. Also, strain 181/25 can be transmitted
experimentally by the natural mosquito vector, Ae. aegypti [25].
To be effective in resource-limited nations that are endemic for
CHIK as well as to combat an epidemic, an ideal CHIK vaccine
would induce rapid and long-lived immunity after a single dose,
have a low risk of reactogenicity and reversion to virulence, and be
inexpensive. Vaccines against arboviral diseases should also have a
low risk of transmission from vaccinated persons via mosquitoes in
the event that viremia occurs, especially those used in non-
endemic regions. Although replication-defective vaccine candi-
dates have been described that emphasize safety [26,27,28], none
has been shown to induce rapid or long-lived immunity after a
single dose, and some may be expensive to produce. In contrast,
live-attenuated vaccines like the yellow fever 17D vaccine [29]
have been spectacularly successful in preventing disease in
developing tropical regions.
To generate a safer and more effective live-attenuated CHIK
vaccine that meets the criteria outlined above, we previously
produced and tested a series of chimeric alphaviruses containing
either Venezuelan equine encephalitis virus (VEEV), eastern
equine encephalitis or Sindbis virus non-structural protein genes
along with the CHIKV structural protein genes [30]. These
vaccines produce robust neutralizing antibody (Ab) responses and
provide complete protection against disease after CHIKV
challenge. However, some residual ability to infect potential
mosquito vectors remains, and attenuation is dependent on an
intact murine interferon response (SCW, unpublished). To
overcome these limitations, we developed a new attenuation
strategy and conducted proof-of-principle studies with another
alphavirus, VEEV vaccine strain TC-83. Both attenuation and
elimination of mosquito infectability relied on the inactivation of
the subgenomic promoter, and addition of a encephalomyocarditis
virus (EMCV) internal ribosome entry sequence (IRES) to drive
translation of the structural protein genes [31]. Chimeric
alphaviruses incorporating the IRES element have also been
generated as vaccine candidates [32]. The EMCV IRES also
mediates inefficient translation in arthropod cells [33], rendering
these mutants unable to infect mosquitoes. However, starting with
the attenuated TC-83 strain, the IRES-based attenuation resulted
in inadequate immunogenicity and the lack of a neutralizing Ab
response.
Here, we implemented this IRES-based vaccine design for
CHIKV using a cDNA clone generated from the wild-type La
Reunion strain [34]. Testing of this novel vaccine candidate in
several murine models indicated that it is highly attenuated, even
in the absence of an intact murine IFN response, is immunogenic
Figure 1. Genetic organization of wild-type CHIKV and the
sequence of the subgenomic promoter. A. Cartoon showing the
locations of the 2 open reading frames encoding the nonstructural
proteins and the subgenomic message encoding the capsid (C) as well
as the envelope glycoproteins E2 and E1. B. Inactivation of the
subgenomic promoter and insertion of the encephalomyocarditis
internal ribosome entry site (IRES) to drive expression of the structural
proteins from the genomic message. C. Wild-type subgenomic
promoter (above) and inactivated promoter sequence (below) with
synonymous mutations in lower-case. Deduced amino acid sequence is
between nucleotide sequences. Red letters represent the subgenomic
promoter region.
doi:10.1371/journal.ppat.1002142.g001
Author Summary
Chikungunya virus (CHIKV) is a mosquito-borne alphavirus
that has reemerged since 2004 to cause millions of cases of
severe and often persistent arthralgia. Because no licensed
vaccine exists to prevent this disease, we utilized an
attenuation approach to produce a live CHIKV vaccine
candidate that elicits a robust, protective immune
response yet causes no detectable disease in mice. It is
also incapable of infecting mosquito vectors, an important
safety feature for a live virus vaccine that may be used in
nonendemic locations to immunize travelers or laboratory
personnel. This vaccine approach, which exploits the
attenuating effect of altering the expression of the
alphavirus structural proteins with a picornavirus IRES,
may be broadly applicable to other alphaviruses that cause
important febrile diseases as well as encephalitis.
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mosquitoes.
Results
Production of recombinant CHIKV/IRES vaccine
candidate
The CHIKV/IRES vaccine candidate was generated in cDNA
form using standard recombinant DNA techniques using the
IRES-based attenuation strategy tested previously in TC-83 [31].
The IRES element was amplified from the original TC-83/IRES
construct including the first 4 codons from the EMCV sequence
that were previously shown to have no effect on viral replication
[31]. The IRES sequence was placed directly downstream from
the subgenomic promoter of the La Reunion (LR) CHIKV
infectious cDNA clone (Fig. 1B) [34]. The subgenomic promoter
was inactivated using 13 synonymous mutations to preserve the
wild-type amino acid sequence of nsP4 (Fig. 1C). The resultant
virus, rescued by electroporation of in vitro-transcribed RNA into
Vero cells, contained a non-functional subgenomic promoter as
indicated by the absence of subgenomic RNA within infected cells
(Fig. 2A).
Titers of CHIKV/IRES collected 30 h after electroporation
were 6610
6 plaque forming units (PFU)/ml, in comparison to
titers of 1.1x10
7 for wild-type (wt) CHIKV strain LR. To assess
replication kinetics, viruses derived from the electroporation were
compared after infection of Vero cells. The CHIKV/IRES
replicated more slowly than 181-25 or wt-CHIKV, requiring
48 hours at 37uC to reach a peak titer of 2.5610
7 PFU/ml. Strain
181-25 replicated almost to peak titer within 24 hours and reached
7.9610
7 PFU/ml. The wt-CHIKV also replicated close to its peak
titer by 24 hours and reached 4.2610
7 (Fig. 2B). Unlike wt-
CHIKV, which produced visible plaques within 48 hours of Vero
cell infection, the CHIKV/IRES plaques were not readily visible
before 3 days of incubation at 37uC. CHIKV/IRES plaques were
0.5–2 mm in diameter, whereas vaccine strain 181/25 produced
2–4 mm and wt CHIKV produced ca. 6 mm plaques under 0.4%
agarose at 3 days post infection (Fig. 2C).
Stability following cell culture passages
To assess phenotypic and genetic stability, CHIKV/IRES was
passaged 10 times in Vero cells at 37uC using a multiplicity of
infection of 0.1 PFU/cell. The plaque morphology remained
heterogeneous but consistent after the 10 passages (Fig. 2C).
Sequencing of reverse transcription-polymerase chain reaction
(RT-PCR) amplicons covering the entire genome revealed no
consensus mutations aside from the presence of adenine insertions
within a poly-A track of the IRES element itself. Plaque purified
clones were sequenced through the IRES to determine the
frequency of these mutations; 8 of 10 plaque clones examined had
7 As like the original cDNA clone and the 10
th passage consensus
sequence. However, 3 biological clones had up to 17 As in this
region. These differences in sequence showed no obvious
correlation with plaque size (data not shown).
CHIKV/IRES was also blind-passaged 5 times in C6/36 Ae.
albopictus cells and the presence of virus was detected by the ability
to produce cytopathic effects (CPE) on Vero cells and by RT-PCR
amplification. Virus was detected only after the first passage,
which presumably reflected residual virus that could not be
washed from the cells after inoculation, and was not detected
thereafter (data not shown). In contrast, the wt-CHIKV strain
replicated in the mosquito cells throughout the passages, with titers
ranging from 3–5610
7 PFU/ml.
Attenuation in infant CD-1 mice
Infant outbred CD1 mice develop CHIK disease similar in
many ways to that seen in humans [35]. We therefore used this
model to evaluate the attenuation of our CHIKV/IRES vaccine
candidate. Cohorts (N=3) of 6-day-old CD1 mice were injected
subcutaneously (SC) with 10
5 PFU (A high dose to increase
sensitivity to detect virulence) of strains 181/25, wt LR, or
CHIKV/IRES, and were sacrificed on days 2, 4, 6, and 8 to
compare viral loads. Blood, brain, and leg tissue (including the
knee) were collected and titrated for infectious virus. The
CHIKV/IRES strain produced no detectable virus in any tissue
measured throughout the sampling period. In contrast, both
vaccine strain 181/25 and wt CHIKV produced measurable and
significantly higher viremia through day 4 (p,0.05)(Fig. 3A).
Surprisingly, vaccine strain 181/25 produced higher viral titers in
leg tissue than wt strain LR, and both wt-CHIKV and 181/25 leg
titers were significantly higher than those of CHIKV/IRES
(p,0.05)(Fig. 3B). The wt CHIKV strain produced significantly
higher brain titers than either vaccine strain on day 2
(p,0.05)(Fig. 3C). These results indicated that CHIKV/IRES is
strongly attenuated in the baby mouse model.
Attenuation in A129 mice
Another murine model for CHIKV pathogenesis is the A129
mouse, which lacks functional type I interferon receptors. This
model has the advantage of producing disease in adult animals,
Figure 2. Replication of CHIKV/IRES in vitro. A. Viral RNA present
in Vero cells 22 hours after infection with CHIKV/IRES and CHIKV strains
LR and 181/25. Slight differences in genomic and subgenomic RNA sizes
of wt-LR strain and 181/25 reflect differences in untranslated sequence
lengths. B. Replication kinetics of vaccine strains CHIKV/IRES and 181/25,
as well as wt CHIKV in Vero cells after infection at a multiplicity of 0.1
PFU/cell. C. Plaque morphology of vaccine strains CHIKV/IRES, CHIKV/
IRES Vero p10, and 181/25, as well as wt-CHIKV 3 days after infection of
Vero cells. * =p,0.05; ** =p,0.001.
doi:10.1371/journal.ppat.1002142.g002
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Cohorts of 10-week-old homozygous A129 mice were injected
intradermally in the footpad with 10
4 PFU (more than 100 LD50
for wt-CHIKV) of either CHIKV/IRES (N=7) or 181/25
(N=4), and negative controls were sham (PBS)-infected (N=6).
Mice infected with the CHIKV/IRES vaccine showed no visible
signs of illness (weight loss, temperature change, ruffling of fur or
hunched posture) during 14 days of observation. Mice receiving
strain 181/25 exhibited significant hyperthermia from day 4–5,
and also showed significant weight loss on day 6 post vaccination
(p,0.05), compared to the more constant temperatures and
weight increases observed in the mice receiving CHIKV/IRES
(Figs. 4A and B). Both CHIKV/IRES and 181/25 produced
viremia in A129 mice, but mean titers were consistently lower for
CHIKV/IRES (Fig. 4C). These data suggested greater attenua-
tion of CHIKV/IRES compared with181/25.
Another sign of disease monitored in A129 mice was swelling of
the feet. For this measurement, mice were vaccinated as described
above and subsequently challenged with 100 PFU of wt-CHIKV
one month post-vaccination in the same foot as the vaccination
site. Two days after vaccination or challenge, the vertical heights
of the hind feet were measured using a caliper at the balls. PBS
and 181/25 vaccination produced small and similar amounts of
swelling (ca. 0.05 mm), while CHIKV/IRES vaccination pro-
duced slightly greater but still minimal swelling of 0.1 mm (Fig. 5).
Sham-vaccinated mice that were challenged showed a strong
Figure 3. Vaccination of 6-day-old CD-1 mice after with
10
6 PFU of wt-CHIKV or vaccine candidates 181/25 or CHIKV/
IRES. A: viremia; B: knee tissue; C: brain. Dashed line shows limit of
detection for the plaque assay. Bars indicate standard deviations.
*= p ,0.05.
doi:10.1371/journal.ppat.1002142.g003
Figure 4. Vaccination of 10-week-old A129 mice. Mice were
inoculated intradermally with 10
4 PFU of CHIKV/IRES or 181/25, or after
sham infected with PBS. A. Temperature. B. Weights. C. Viremia
determined using qRT-PCR. Bars indicate standard deviations. N=7 for
CHIKV/IRES and N=4 for strain 181/25. * = p,0.05. and ** = p,0.001.
doi:10.1371/journal.ppat.1002142.g004
Figure 5. Foot swelling for 10-week-old A129 mice after
intradermal vaccination with 10
4 PFU of CHIKV/IRES or 181/
25. The mice were challenged 30 days later with wt-CHIKV and a post-
challenge measurement was taken 48 hours after. Foot thickness was
measured with a caliper as the vertical height of the hind feet at the
balls. Bars indicate standard deviations. N=7 for CHIKV/IRES and N=4
for strain 181/25. * =p,0.05. and ** =p,0.001.
doi:10.1371/journal.ppat.1002142.g005
Novel Chikungunya Vaccine Approach
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thickness. In contrast, both vaccines protected significantly against
swelling (p,0.001) with no significant difference between 181/25
and CHIKV/IRES.
Attenuation of the 2 vaccine candidates was also compared by
infection of 3-week-old A129 mice. Cohorts of 5 were injected
intradermally with 10
4 PFU (.100 LD50 for wt-CHIKV) of either
181/25 or CHIKV/IRES. The mice were monitored for weight
and survival. There was no significant difference between the
weight changes of the two cohorts (Fig. 6A). All animals that
received the 181/25 vaccine died or had to be euthanized by day 8
(Fig. 6B). In contrast, none of the animals inoculated with the
CHIKV/IRES vaccine showed any signs of illness and all survived
to the end of the study 14 days after infection.
Immunogenicity and efficacy in A129 mice
All A129 mice that received vaccine candidates 181/25 (N=4)
or CHIKV/IRES (N=7) at a dose of 10
4 PFU seroconverted. All
titers measured 35 days after vaccination exceeded 320, except for
one mouse immunized with strain 181/25 that had a PRNT80 titer
of 160. None of the animals that received CHIKV/IRES or 181/
25 showed a significant temperature change (data not shown) or
any other signs of illness (as described above) after challenge with
100 PFU of wt CHIKV, and all survived until day 14 after
challenge, when the study was terminated. Mice vaccinated with
181/25 exhibited stable or slightly increasing weight after
challenge, while the CHIKV/IRES-vaccinated mice lost some
weight on days 8 and 9 post challenge, then recovered. In sharp
contrast, sham-vaccinated animals rapidly lost weight before
succumbing to infection (Fig. 7A and B). Both vaccines were
significantly (Kaplan-Meier, p,0.05) and equally efficacious in
preventing fatal CHIK in the A129 model.
The ability of the CHIKV/IRES vaccine candidate to protect
against disease was also measured histopathologically in A129
mice after wt-CHIKV challenge. Because unprotected mice die
before muscle or joint lesions develop (SCW, RS, unpublished), we
examined the spleen, where earlier lesions occur. Cohorts of three
8–10-week-old A129 mice were vaccinated intradermally in the
footpad with either 10
4 PFU of CHIKV/IRES or were sham-
vaccinated with PBS. One mouse from each cohort was sacrificed
4 days post vaccination, and the remaining 2 mice were challenged
with 100 PFU of wt-CHIKV at 26 days post-vaccination, then
sacrificed 4 days post-challenge. The spleens of the sham-
vaccinated mice challenged with CHIK-LR exhibited severe
necrosis with markedly reduced numbers of small lymphocytes in
the mantle and marginal zones. Only the central portion of the
remnant lymphoid follicle remained. In addition, monocytoid cells
with abundant eosinophilic cytoplasm in the interfollicular region
were observed (Fig. 8C). In contrast, the spleens of animals
receiving the vaccine as well as CHIKV/IRES-vaccinated mice
challenged with wt-CHIKV (Fig. 8B & D) exhibited normal
splenic architecture with intact lymphoid follicles and appropriate
quantities of white and red pulp. The key histopathologic finding
was the absence of any necrosis in the CHIK/IRES-vaccinated
animals, when compared to the sham-vaccinated mice.
Duration of immunity in A129 mice
To evaluate the duration of immunity and protection after
vaccination, cohorts of six A129 mice were immunized with
CHIKV/IRES as described above, bled 21, 42, 56 and 92 days
later, then challenged 94 days after vaccination. Similar to the
results described above, no significant weight loss, footpad
swelling, or other signs of disease were noted after vaccination
Figure 6. Virulence for 3-week-old A129 mice for strains 181/25
and CHIKV/IRES. A. Weight post-vaccination. B. Survival post-
vaccination.
doi:10.1371/journal.ppat.1002142.g006
Figure 7. Weight and survival in 10-week-old A129 vaccinated
with CHIKV/IRES, 181/25, or PBS, then challenged with wt-
CHIKV (100 PFU). A. Weight post-challenge. B. Survival post-
challenge. * =p value,0.05.
doi:10.1371/journal.ppat.1002142.g007
Novel Chikungunya Vaccine Approach
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PRNT80 titers prior to challenge were all $640. After challenge
with 100 PFU of wt-CHIKV, vaccinated animals were signifi-
cantly protected against foot swelling, fever and mortality (6/6
sham-vaccinated mice died by day 5, whereas all CHIKV/IRES-
vaccinated mice survived until day 14 when the study was
terminated)(Fig. 9A and B). The sham-vaccinated group experi-
enced significant hyperthermia on day 2, followed by significant
hypothermia on day 3 as the animals became moribund (Fig. 9C).
There were no significant differences in weight change between
the two cohorts (Fig. 9D).
Immunogenicity and efficacy in adult C57BL/6 mice
To test the immunogenicity and efficacy of the CHIKV/IRES
vaccine candidate compared with strain 181/25 in immunocom-
petent mice, cohorts (N=9-10) of 3-week-old C57BL/6 mice were
vaccinated SC with 10
5 PFU, or with PBS as negative controls.
Although 14-day-old and adult C57BL/6 mice develop lesions in
the leg after footpad inoculation with wt CHIKV [37,38], we used
a more stringent, lethal intranasal (IN) challenge C57BL/6 model
with the neuroadapted Ross CHIKV strain for efficacy testing
[30]. Three weeks after infection, all mice were bled and Ab titers
were measured using an 80% plaque reduction neutralization test
(PRNT80). The mean Ab titers in response to strains CHIKV/
IRES and 181/25 were nearly equal, with all animals exhibiting
PRNT80 titers $20 (p.0.1; Table 1). The mice were then
challenged IN with 10
6 PFU of the Ross CHIKV strain. All
vaccinated animals survived without any signs of disease (weight
loss, temperature change, ruffling of fur or hunched posture)
through day 14. One of ten sham-vaccinated mice died on day 9
and 6 died on day 10 after challenge. These results demonstrated
the immunogenicity and significant efficacy of the CHIKV/IRES
vaccine candidate in immunocompetent mice.
Passive transfer of immune sera
To confirm that neutralizing antibodies mediated protection of
A129 mice from CHIKV challenge, pooled serum collected 21
days after immunization of A129 mice was inoculated intraper-
itoneally into naı ¨ve 6–7-week-old A129 mice (N=5) either
undiluted or at dilutions of 1:2 or 1:4; undiluted normal mouse
serum was used as a negative control. Following challenge with
100 PFU of wt CHIKV, mortality was monitored for 15 days. All
Figure 8. Representative splenic histopathology of A129 mice post-vaccination and –challenge, 20X magnification. A. PBS-vaccinated
animal 4 days post-vaccination. B. CHIKV/IRES-vaccinated animal, 4 days post-vaccination. C. PBS-vaccinated animals, 4 days post-challenge; I: center
of remnant lymphoid follicle. II: proteinacious debris. III: monocytoid cells. D. CHIKV/IRES vaccinated animals, 4 days post-challenge.
doi:10.1371/journal.ppat.1002142.g008
Novel Chikungunya Vaccine Approach
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compared with those that received normal mouse serum (Kaplan
Meier, p,0.001) and greater dilutions of the immune serum
resulted in reduced survival (Fig. 10). These data indicate that
neutralizing antibodies protected against fatal CHIK and indicate
a correlation between Ab levels and protection.
Mosquito infections in vivo
To confirm that the CHIKV/IRES strain was incapable of
replicating in mosquitoes, cohorts of 20 adult female Ae. albopictus,
a highly susceptible urban vector [20], were inoculated intratho-
racically with ca. 1.0 mlo fa1 0
4 PFU/ml suspension of either
CHIKV/IRES or the wt LR strain. Intrathoracic infection was
used rather than oral exposure because mosquitoes are uniformly
susceptible to small CHIKV doses delivered via this route, whereas
the oral portal of entry is less permissive even after large doses.
After 7 days of incubation at 27uC, mosquitoes were triturated and
serial 10-fold dilutions were tested for virus by inoculation of Vero
cells followed by examination for cytopathic effects (CPE) through
day 7. Mosquitoes inoculated with CHIKV/IRES as well as PBS-
inoculated negative control mosquitoes produced no detectable
CPE. In contrast, all 20 mosquitoes receiving wt CHIKV
produced extensive CPE on the Vero cells. To ensure that
temperature sensitive or host-restricted mutants were not gener-
ated following mosquito infection, RT-PCR targeting the 59 end of
the capsid gene was also used to detect viral RNA. No amplicons
were detected from the CHIKV/IRES-infected mosquitoes by gel
electrophoresis, whereas all mosquitoes injected with wt CHIKV
produced strong bands of the expected size (Fig. S1).
Figure 9. Duration of immunity in A129 mice. Mice were vaccinated at 10 weeks of age and challenged 94 days later. A. Sham-vaccinated mice
experienced significant foot swelling compared to CHIKV/IRES-vaccinated mice. B. All vaccinated mice survived challenge while sham-vaccinated
mice succumbed to infection by day 5. C. Sham-vaccinated animals experienced significant hyperthermia on day 2 and hypothermia on day 3, while
vaccinated animals maintained relatively stable temperatures. D. There was no significant difference in weight change between the cohorts.
*= p ,0.05; ** =p,0.001.
doi:10.1371/journal.ppat.1002142.g009
Table 1. Seroconversion of adult C57BL/6 mice after
vaccination.
Vaccine CHIKV/IRES 181/25 Sham
% Seroconversion 100 100 0
Mean PRNT80 titer 62 67 ,20
Standard deviation 44 20
9 animals per cohort, assayed 28 days after vaccination with 10
5 PFU.
doi:10.1371/journal.ppat.1002142.t001
Figure 10. Protection of mice with passive transfer of immune
serum. Survival of 10-week-old A129 mice after intraperitoneal
inoculation of diluted or undiluted immune CD-1 mouse serum from
animals vaccinated with CHIKV/IRES, and challenge with 100 PFU of wt-
CHIKV. N=5.
doi:10.1371/journal.ppat.1002142.g010
Novel Chikungunya Vaccine Approach
PLoS Pathogens | www.plospathogens.org 7 July 2011 | Volume 7 | Issue 7 | e1002142Discussion
Nearly 80 years after the introduction of the first vaccine against
an arboviral disease, yellow fever [39], vaccination remains the
most effective method to protect against arboviruses and many
other infectious agents. In the case of CHIK, the 181/25 live-
attenuated vaccine developed during the 1980s showed promise in
preclinical studies [23] but was mildly reactogenic in human trials
[24]. More recent vaccine development has focused on inactivated
[26], DNA [27] or virus-like particle approaches [28]. However, in
our opinion, the requirements for multiple doses administered over
several weeks and/or the higher cost of such vaccines, as well as
the probability that boosters will be required to maintain
immunity, will limit their usefulness in the developing nations of
Africa and Asia where CHIKV is endemic. We have therefore
focused on live-attenuated vaccines to prevent both endemic and
epidemic CHIK.
The maturity of reverse genetic technology has provided
unprecedented opportunities for manipulation of the alphaviral
genome to improve attenuation strategies [40]. Thus, unlike
traditional attenuation approaches that rely on cell culture
passages, which typically result in attenuation that depends only
on small numbers of attenuating point mutations [41], alternative
genetic strategies such as viral chimeras offer the promise of more
stable attenuation [30,42,43,44]. In addition to the risk of
reactogenicity, attenuation based on small numbers of mutations
can also result in residual alphavirus infectivity for mosquito
vectors. This risk, which was underscored by the isolation of the
TC-83 VEEV vaccine strain from mosquitoes in Louisiana during
an equine vaccination campaign designed to control the 1971
epidemic [45], is especially high when a vaccine that relies on a
small number of point mutations is used in a nonendemic location
that could support a local transmission cycle.
To overcome the aforementioned limitations, we exploited the
finding that the EMCV IRES sequence functions inefficiently for
translation in insect cells [33], yet can replace the alphavirus
subgenomic promoter to mediate translation of the structural
polyprotein open reading frame from the genomic RNA in
mammalian cells [31,32]. The resultant CHIKV strain replicated
efficiently in Vero cells, an acceptable vaccine substrate, and
exhibited a stable plaque morphology and consensus genome
sequence after 10 passages in this cell line. The CHIKV/IRES
vaccine candidate was unable to replicate in mosquito cells or in
the mosquito vector, Ae. albopictus, an important safety feature for
an live arbovirus vaccine that may be administered to travelers or
laboratory workers in nonendemic locations.
Attenuation, immunogenicity and efficacy of the CHIKV/
IRES vaccine candidate was assessed alongside that of the 181/25
CHIKV strain, which is highly immunogenic in humans and other
animals yet inadequately attenuated. The goal was to equal the
immunogenicity of the 181/25 vaccine strain but to achieve
greater attenuation. Using infant and adult immunocompetent
[35] and interferon type I receptor-deficient mouse models [36],
we demonstrated that CHIKV/IRES met both goals. As
measured by survival and weight gain or maintenance,
CHIKV/IRES was similarly or better attenuated than 181/25
in multiple mouse models, yet generated comparable neutralizing
Ab titers and nearly complete protection against disease or
mortality after CHIKV challenge. Immunity and protection were
maintained for at least 3 months. Viremia after CHIKV/IRES
vaccination was never detected in infant CD-1 mice, and was
transiently present at a very low level in immunocompromised
A129 mice, an important attenuation phenotype considering that
viremia could potentially lead to mosquito infection. However,
even in the unlikely event that vaccination of an immunocom-
promised human led to viremia, the mosquito-incompetent
phenotype discussed above should prevent transmission. The only
measure of efficacy for which strain 181/25 exhibited a slight
superiority was in the prevention of footpad swelling post
challenge; CHIKV/IRES-vaccinated A129 mice challenged with
wt-CHIKV exhibited a greater mean of 0.15mm swelling versus
only 0.09 mm for strain 181/25. However, both vaccines provided
significant protection compared with sham-vaccination.
Splenic histopathology was used as a second measure of
protection. Mice challenged with wt-CHIKV after sham vaccina-
tion developed severe necrosis along with a monocytoid infitrate.
in contrast, the CHIKV/IRES vaccine induced no splenic
histopathology and protected against splenic lesions upon
challenge.
Previous attempts to use the EMCV IRES to generate an
alphavirus vaccine used the VEEV live-attenuated vaccine strain
TC-83 [30]. Although these studies succeeded in eliminating the
ability of TC-83 to infect mosquito vectors, immunogenicity was
reduced to the point where most vaccinated mice did not develop
detectable neutralizing antibodies (although significant protection
against challenge was still detected). In contrast, our CHIKV
vaccine started with the genetic backbone of a virulent wt
alphavirus (LR) (Fig. 1A), and robust immunogenicity was
maintained despite strong attenuation. These results suggest that
the IRES attenuation level may be optimal when applied to other
wild-type alphavirus backbones. The application of this platform
for attenuation is now being applied to Venezuelan, western, and
eastern equine encephalitis viruses to test this hypothesis.
In summary, a novel CHIK vaccine candidate, CHIKV/IRES,
was generated by manipulation of the structural protein expression
of a wt-CHIKV strain via the EMCV IRES. This vaccine
candidate exhibits a high degree of murine attenuation that is not
dependent on an intact interferon type I response, yet is highly
immunogenic and protects against CHIKV challenge. This
promising vaccine candidate is being tested in nonhuman primates
to determine if it is suitable for evaluation in humans.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committees of the University of Texas Medical Branch or the
University of Wisconsin.
Cell cultures
Vero African green monkey kidney cells were obtained from the
American Type Cell Culture (Bethesda, MD). The cells were
maintained at 37uC in Eagles minimum essential media (MEM)
supplemented with 10% fetal bovine serum (FBS), penicillin and
streptomycin. C6/36 Ae. albopictus cells were also maintained in
MEM containing 10% FBS at 32uC and supplemented with 10%
tryptose phosphate.
Production of plasmid and sequencing
The CHIKV cDNA clone containing the EMCV IRES with
the subgenomic promoter ablated using 13 synonymous mutations
(CHIKV/IRES) was produced using standard recombinant DNA
techniques in which the infectious clone of La Reunion strain (LR)
described previously was used as a template [34]. This CHIKV
clone, a gift from Stephen Higgs, contains an SP6 bacteriophage
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viral RNA. The IRES sequence was PCR amplified from a cDNA
clone described previously [31]. The inactivation of the sub-
genomic promoter was done using site-specific mutagenesis. An
intermediate construct encoding the 39 end of the nsP4 gene
through the subgenomic promoter was produced using PCR with
high fidelity Phusion DNA polymerase from Finnzymes (Espoo,
Finland). The resultant amplicon was cloned into a shuttle vector,
prS2, and was sequenced using the BigDye kit (Applied
Biosystems, Foster City, CA). The 59 end of capsid gene from
the LR strain was amplified using PCR with an overhang
complementary to the IRES sequence. The IRES-containing and
capsid fragments were then joined using fusion PCR, and this
fragment was cloned back into the shuttle vector and resequenced.
The IRES/Capsid fragment and the mutated subgenomic
fragment were finally ligated together through the SpeI site
introduced into both fragments. The completed insert was then
cloned into the LR backbone and this final construct was
completely sequenced.
RNA transcriptions, transfections, and virus production
Large-scale plasmid purification was done using CsCl prepara-
tions. The purified DNA was then linearized using NotI restriction
endonuclease (New England BioLabs, Ipswich, MA), and a small
sample was analyzed on a 1.2% agarose gel to verify linearization.
The remaining DNA was transcribed using an Ambion SP6 In
vitro transcription kit. The RNA was quantified and used to
electroporate Vero cells using a BTX ECM 830 electroporator.
Briefly, two T-150 flasks containing 90% confluent Vero cells were
trypsinized and washed 3 times in RNAse-free DPBS. The cells
were resuspended in 700 ml of DPBS and 10 mg of RNA was
added. The solution was placed in a 4mm cuvette and was pulsed
2 times at 250v for 10 msec at 1 sec intervals. The cells were then
left at room temperature for 10 minutes before being plated in T-
75 flasks. The virus was harvested at 24 hours post-electroporation
and centrifuged at 7716g. Supernatant was collected and titered
by plaque assay on Vero cells.
Cell culture passages and replication curves
The CHIKV/IRES vaccine candidate was passaged in Vero
and C6/36 cells to assess phenotypic and genetic stability. T-25
flasks were grown to 90-95% confluency, then were infected at a
multiplicity (MOI) of 0.1 Vero PFU/cell. Following 30 h of
incubation at 37uCo r3 2 uC, respectively, the medium was
diluted and used to infect another flask with a MOI of 0.1.
Following 10 serial passages, consensus sequences were deter-
mined for both passaged populations and plaque-purified
biological clones by RT-PCR amplification and amplicon
sequencing. We also selected 10 well-isolated, random plaques,
harvested virus using a plastic micropipette tip. The agar plug
containing the plaque was placed in 300 ml of MEM containing
2% FBS and RNA was extracted using TRIzol LS (Invitrogen,
Carlsbad, CA). RT-PCR and sequencing were performed as
described above. Vero plaque sizes were measured and
compared to assess stability.
Replication kinetics was measured in 35 mm 6-well plates with
duplicates for each virus tested. The wells were seeded to a
confluency of 95% using Vero cells. Media was removed and they
were infected at an MOI of .1 for one hour. Then 2.1 ml of
DMEM containing 5% FBS was added. A 0 time point was
immediately removed (100 ml). At each of the remaining time
points 12, 24, 36 and 48 100 ml was removed and replaced. The
samples were tittered as described above.
Virus and antibody titers
Depending on containment requirements and sensitivity needs,
virus stocks and experimental samples were titered by plaque assay as
previously described [46] or were estimated using quantitative real-
time PCR with dilutions of virus to generate standard curves from
which PFU titers could be extrapolated. This assay used primers (59-
GAYCCCGACTCAACCATCCT-39)a n d( 5 9-CATMGGGCAR-
ACGCACTGGTA-39)a n dt h ep r o b e( 5 9-AGYGCGCCAGCAAG-
GAGGAKGATGT-39) which contained the dye FAM. Ab titers
were measured using plaque reduction neutralization tests with 80%
reduction endpoints [46].
RNA replication
Vero cells were infected on 35 mm
2 6 well plates at an MOI of
20. The media was removed 18 hours after infection and replaced
with .8 ml of complete media with 1 mg/ml of actinomycin D from
Sigma, and 20 mCI of [5,6-
3H] uridine from Moravak Biochem-
icals (Brea, CA.). The cells were then incubated for 4 hours and
RNA is removed by TRIzol extraction. The RNA was placed into
a sodium phosphate buffer containing DMSO and glyoxal at 50uC
for 1 hour. The RNA was loaded into a 1% agarose gel and run at
150 v for 3–4 hours. The gel was then washed twice in methanol
for 30 minutes. Then a 2.5% PPO and methanol solution was
placed with the gel overnight. The gel was washed with DI water
to precipitate the PPO and the gel was then dried. The gel is then
placed with X-OMAT AR film (Kodak), at 280uC for 8 hours.
Animal studies
Five-to-seven-day-old CD1 outbred mice [35] were obtained
from Charles River (Wilmington, MA). These animals were
infected subcutaneously (SC) with 10
5 PFU and were serially
sacrificed on days 2, 4, 6, 8, and 10. Blood, brain, and hind
femoral tissues were collected for assays of virus content. C57BL/6
mice were obtained from Jackson labs (Bar Harbor, ME) and used
in challenge experiments as described previously [30]. Briefly, the
animals were infected SC at 3 weeks of age with 10
5 PFU in the
hind leg and observed for signs of illness for 21 days. Then, they
were challenged intranasally (IN) with 10
6.5 PFU of the neuroa-
dapted Ross CHIKV strain. The animals were observed daily for
illness and were sacrificed when they became moribund.
A129 mice were bred at the University of Wisconsin from a
breeding pair obtained from B & K ltd. Grimston, England.
Animals 3 or 10 weeks of age, were infected with 1x10
4 PFU of
vaccine strains ID in the left rear footpad. Footpad measurements
were taken 48 hours post vaccination with a caliper as the vertical
height of the hind feet at the balls. The animals were maintained
for 38 days and bled on days 21 and 35. These animals were then
challenged with 100 PFU of wt CHIKV and were monitored for
morbidity and mortality. All animals were euthanized by CO2
overdose if they became moribund. A129 animals were used for a
longitudinal study of protection in which they were challenged
with 100 PFU ID of wt-CHIKV 94 days after being vaccinated.
Tissues were fixed in 10% neutral buffered formalin (RICCA
Chemical Company, Arlington, TX.). Bone tissue was decalcified
overnight using fixative/decalcifier (VWR International, Radnar,
PA.). Tissue was then embedded in paraffin wax and 5 um
sections were cut for analysis. Sections for hematoxylin and eosin
staining were deparaffinized in Xylene for 15 minutes. Sections
were then rehydrated in ethanol and ethanol/water mixtures as
follows: 100% ethanol for 9 minutes, 95% ethanol/5% deionized
water for 3 minutes, 80% ethanol/20% deionized water for 5
minutes. Sections were then stained with hematoxylin (Richard-
Allan Scientific) for 3 minutes and then rinsed with deionized
water. Sections were then rinsed in tap water for 5 minutes and
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for 5 minutes. Sections were then rinsed in tap water for 2 minutes
and then in deionized water for 2 minutes. Sections were then
stained in eosin (Richard-Allan Scientific) for 30 seconds. They
were then dehydrated as follows: 95% ethanol/5% deionized
water for 15 minutes, 100% ethanol for 15 minutes and then
Xylene (Richard-Allan Scientific) for 15 minutes. Cover slips were
applied to slides using Permount (Fisher Scientific) and dried
overnight. Deparaffinizing and hematoxylin-eosin staining was
performed on the Varistain Gemini ES (Shandon, Thermo Fisher
Scientific).
All animal studies were approved by the UTMB and/or the
Univ. Wisconsin Institutional Animal Care and Use Committee.
Mosquito infections
An Ae. albopictus colony established in 2003 from mosquitoes
collected in Galveston, TX was used for these experiments. This
species was selected because it is highly susceptible to the LR
CHIKV strain [20]. Adult female mosquitoes collected 3–4 days
post-eclosion were anesthetized using a chill table (Bioquip,
Rancho Dominguez, CA) and were then injected intrathoracically
with ca. 1.0 mLo fa1 0
4 Vero PFU/ml virus stock. The mosquitoes
were incubated for 7 days at 27uC with 10% sucrose provided ad
libitum. The mosquitoes were then frozen and triturated in MEM
containing 2% FBS and fungicide using a Tissuelyser II (Qiagen,
Venlo, Netherlands) for 2 min. Following centrifugation for 10
minutes at 10,0006G, the supernatant was plated on Vero cells
using 96 well plates. The cells were infected for 1 hour at 37uC
and then covered with 2% FBS containing MEM and allowed to
incubate for 48 hr to measure CPE.
RT-PCR
RNA was collected through Qiagen RNeasy columns (Qiagen,
Venlo, Netherlands) or TRIzol LS (Invitrogen) using the
manufacturer’s protocols. 130 ml of sample were taken from the
mosquito homogenates and the RNA was collected. The RNA was
then amplified via RT-PCR using a Titan single step RT-PCR kit
(Roche, Basel, Switzerland). The primers used to amplify annealed
to the 59end of capsid, 59-TGGCCTTTAAGCGGTC-39 and 59-
TATGGTCTTGTGGCTTTATAGAC-39.
Statistics
Student’s T-tests were performed using Excel (Microsoft,
Redmond, WA). ANOVA tests were performed using SPSS v18
(IBM Corporation, Somers, NY). Kaplan-Meier tests were
performed using Prism 5 (GraphPad Software, La Jolla, CA). P-
values ,0.05 were considered significant. Negative data points
were counted at one-half of the corresponding limit of detection
for statistical analyses.
Supporting Information
Figure S1 Detection of CHIKV RNA in intrathoracically
inoculated mosquitoes using RT-PCR. Mosquitoes were
injected with ca. 1 mlo fa1 0
4 PFU/ml virus stock or sham
inoculated with PBS, and harvested 7 days later. Viral RNA was
extracted and subjected to RT-PCR targeting the capsid protein
gene. PCR products were electrophoresed on a 1% agarose gel
and DNA was stained with ethidium bromide. Arrow shows the
expected amplicon size of 565 bp.
(TIF)
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